相关实验视频
Updated: Jun 8, 2025
10:05
Ganglioside Extraction, Purification and Profiling
Published on: March 12, 2021
4.5K
对于3型脊髓小脑缩性无力症,氏体GM1脉冲治疗对平行组,双盲,随机,受控试验的潜在疾病改变效应
Yong-Kang Chen1,2, Hai-Yan Tian1, Qing-Yong Zhu1
1Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
概括
高剂量的甘地化物GM1 (甘地化物-单酸) 脉冲治疗显著改善了3型SCA3 (Spinocerebellar ataxia type 3) 患者的动力衰竭症状. 这种安全有效的治疗方法为治疗这种神经退行性疾病提供了新的希望.
科学领域:
- 神经退行性疾病 神经退行性疾病
- 临床神经科学 临床神经科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 3型脊髓小脑动症 (SCA3) 是一种严重的遗传性神经退行性疾病,目前没有治愈方法.
- 迫切需要有效的SCA3治疗策略来改善患者的治疗结果.
研究的目的:
- 评估高剂量氏体GM1 (氏体-单酸) 脉冲治疗在SCA3.3患者中的安全性和有效性.
- 为了比较高剂量GM1,低剂量GM1和安慰剂对抗毒性症状和功能状态的影响.
主要方法:
- 一项随机对照试验涉及48名SCA3患者,他们被分配给高剂量GM1,低剂量GM1或安慰剂4周.
- 主要疗效终点:在治疗后12周内,性衰竭评估和评分 (SARA) 评分的变化.
- 二级终点包括国际合作性性衰竭评分表 (ICARS),巴特尔日常生活活动指数 (ADL) 和血和脑脊液 (CSF) 中的GABA水平.
主要成果:
- 与低剂量GM1 (+0.34) 和安慰剂 (+0.73) 相比,高剂量GM1治疗导致SARA得分显著降低 (-3.80).
- 在高剂量GM1组中,ICARS得分,ADL功能和GABA水平也得到了改善.
- 所有治疗方案都耐受良好,没有报告任何重大安全问题.
结论:
- 高剂量的GM1脉冲治疗在改善SCA3患者的无氧性症状方面表现出显著的有效性.
- 氏体GM1代表了一种有前途的治疗药物,用于治疗3型脊髓小脑动症.
相关概念视频
01:28Drugs Acting on Autonomic Ganglia: Blockers
965
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
965
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K